A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Anixa Biosciences Inc stock. As of the latest transaction made, Renaissance Technologies LLC holds 10,673 shares of ANIX stock, worth $28,710. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,673
Holding current value
$28,710
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.21 - $3.48 $23,587 - $37,142
10,673 New
10,673 $33,000
Q1 2024

May 13, 2024

BUY
$3.08 - $5.02 $211,904 - $345,375
68,800 New
68,800 $215,000
Q3 2023

Nov 14, 2023

SELL
$2.97 - $3.87 $146,421 - $190,791
-49,300 Reduced 83.14%
10,000 $33,000
Q2 2023

Aug 11, 2023

BUY
$3.0 - $5.97 $113,994 - $226,848
37,998 Added 178.38%
59,300 $190,000
Q1 2023

May 12, 2023

SELL
$3.86 - $5.0 $102,668 - $132,990
-26,598 Reduced 55.53%
21,302 $92,000
Q4 2022

Feb 13, 2023

SELL
$3.78 - $5.81 $35,154 - $54,033
-9,300 Reduced 16.26%
47,900 $204,000
Q3 2022

Nov 14, 2022

SELL
$2.81 - $6.15 $80,596 - $176,394
-28,682 Reduced 33.4%
57,200 $281,000
Q2 2022

Aug 12, 2022

SELL
$2.55 - $4.1 $353,871 - $568,969
-138,773 Reduced 61.77%
85,882 $263,000
Q1 2022

May 13, 2022

SELL
$2.5 - $3.42 $265,362 - $363,015
-106,145 Reduced 32.09%
224,655 $616,000
Q4 2021

Feb 11, 2022

BUY
$2.88 - $5.5 $341,568 - $652,300
118,600 Added 55.89%
330,800 $982,000
Q3 2021

Nov 12, 2021

BUY
$3.57 - $5.6 $313,092 - $491,125
87,701 Added 70.44%
212,200 $1.01 Million
Q2 2021

Aug 13, 2021

BUY
$3.46 - $4.92 $430,766 - $612,535
124,499 New
124,499 $483,000
Q2 2020

Aug 13, 2020

SELL
$1.53 - $3.06 $49,290 - $98,580
-32,216 Closed
0 $0
Q1 2020

May 14, 2020

BUY
$1.35 - $4.06 $43,491 - $130,796
32,216 New
32,216 $51,000

Others Institutions Holding ANIX

About Anixa Biosciences Inc


  • Ticker ANIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,661,700
  • Market Cap $82.5M
  • Description
  • Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the...
More about ANIX
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.